Advertisement

Patch Testing in Drug Eruptions

  • Esen Özkaya
  • Kurtuluş Didem Yazganoğlu
Chapter

Abstract

Patch testing is a method carried out by dermatologists to evaluate type IV hypersensitivity reactions. It is the gold standard in the diagnosis of allergic contact dermatitis. Based on the recent knowledge on the involvement of different subtypes of type IV hypersensitivity reactions in the immunopathogenesis of drug eruptions (Table  1.1), patch testing is also of particular value in determining the responsible drug in certain drug eruptions such as eczematous eruption, maculopapular/morbilliform eruption, fixed drug eruption, photoallergic drug eruption, drug-induced Baboon syndrome (BS)/symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), and acute generalized exanthematous pustulosis (AGEP) as a first-step diagnostic method. It is also helpful in identifying the possible cross-reactive drugs and safe alternatives. Photopatch testing should be performed if there is suspicion of photoallergic drug eruptions.

Keywords

Drug eruption Patch test Photopatch test Cardiovascular drugs Commercial drug Patch testing in loco Serial dilution Tape stripping Prick/scratch/intradermal tests with late readings Clinical relevance 

References

  1. 1.
    Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology. 2005;209:209–16.PubMedGoogle Scholar
  2. 2.
    Hug K, Yawalkar N, Helbling A, Pichler WJ. Scratch-patch and patch testing in drug allergy-an assessment of specificity. J Investig Allergol Clin Immunol. 2003;13:12–9.PubMedGoogle Scholar
  3. 3.
    Friedmann PS. Patch testing in drug allergy. Curr Opin Allergy Clin Immunol. 2010;10:291–6. doi: 10.1097/ACI.0b013e32833aa54d.PubMedGoogle Scholar
  4. 4.
    Barbaud A, Gonçalo M, Bruynzeel D, Bircher A. European society of contact dermatitis. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis. 2001;45:321–8.PubMedGoogle Scholar
  5. 5.
    Dickel H, Goulioumis A, Gambichler T, Fluhr JW, Kamphowe J, Altmeyer P, et al. Standardized tape stripping: a practical and reproducible protocol to uniformly reduce the stratum corneum. Skin Pharmacol Physiol. 2010;23:259–65. doi: 10.1159/000314700.PubMedGoogle Scholar
  6. 6.
    Mahajan VK, Handa S. Patch testing in cutaneous adverse drug reactions: methodology, interpretation, and clinical relevance. Indian J Dermatol Venereol Leprol. 2013;79:836–41. doi: 10.4103/0378-6323.120751.PubMedGoogle Scholar
  7. 7.
    Isaksson M, Bruze M. Contact allergen of the year: corticosteroids. Dermatitis. 2005;16:3–5.PubMedGoogle Scholar
  8. 8.
    Özkaya E. Fixed drug eruption: state of the art. J Dtsch Dermatol Ges. 2008;6:181–8.PubMedGoogle Scholar
  9. 9.
    Chemotechnique Diagnostics. Patch test products 2013. http://www.chemotechnique.se/Catalogue.htm. Brial katalog. Accessed 26 Apr 2014.
  10. 10.
    Gonçalo M, Fernandes B, Oliveira HS, Figueiredo A. Epicutaneous patch testing in drug eruptions. Contact Dermatitis. 2000;42(Suppl 2):22.Google Scholar
  11. 11.
    Cham PMH, Warshaw EM. Patch testing for evaluating drug reactions due to systemic antibiotics. Dermatitis. 2007;18:63–77.PubMedGoogle Scholar
  12. 12.
    Häusermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis. 2004;51:297–310.PubMedGoogle Scholar
  13. 13.
    Barbaud A, Tréchot P, Granel F, Lonchamp P, Faure G, Schmutz JL, et al. A baboon syndrome induced by intravenous human immunoglobulins: report of a case and immunological analysis. Dermatology. 1999;199:258–60.PubMedGoogle Scholar
  14. 14.
    Sánchez-Morillas L, Reaño Martos M, Rodríguez Mosquera M, Iglesias Cadarso A, Pérez Pimiento A, Domínguez Lázaro AR. Baboon syndrome due to pseudoephedrine. Contact Dermatitis. 2003;48:234.PubMedGoogle Scholar
  15. 15.
    Schultz ES, Diepgen TL. Clinical characteristics and the causes of the baboon syndrome. Dermatosen. 1996;44:266–9.Google Scholar
  16. 16.
    Ohtoshi S, Kitami Y, Sueki H, Nakada T. Utility of patch testing for patients with drug eruption. Clin Exp Dermatol. 2014;39:279–83. doi: 10.1111/ced.12239.PubMedGoogle Scholar
  17. 17.
    Ozkaya E. Topical provocation in fixed drug eruption due to metamizol and naproxen. Clin Exp Dermatol. 2004;29:419–22.Google Scholar
  18. 18.
    Wilkinson DS, Fregert S, Magnusson B, Bandmann HJ, Calnan CD, Cronin E, et al. Terminology of contact dermatitis. Acta Derm Venereol. 1970;50:287–92.PubMedGoogle Scholar
  19. 19.
    Alanko K, Stubb S, Reitamo S. Topical provocation of fixed drug eruption. Br J Dermatol. 1987;116:561–7.PubMedGoogle Scholar
  20. 20.
    Özkaya E, Yazganoglu KD. Sequential development of eczematous type multiple drug allergy to unrelated drugs. J Am Acad Dermatol. 2011;65:e26–9.PubMedGoogle Scholar
  21. 21.
    Özkaya E. Eczematous-type multiple drug allergy from isoniazid and ethambutol with positive patch test results. Cutis. 2013;92:121–4.PubMedGoogle Scholar
  22. 22.
    Lee AG, Anderson R, Kardon RH, Wall M. Presumed “sulfa allergy” in patients with intracranial hypertension treated with acetazolamide or furosemide: cross-reactivity, myth or reality? Am J Ophthalmol. 2004;138:114–8.PubMedGoogle Scholar
  23. 23.
    Wulf NR, Matuszewski KA. Sulfonamide cross-reactivity: is there evidence to support broad cross-allergenicity? Am J Health Syst Pharm. 2013;70:1483–94. doi: 10.2146/ajhp120291.PubMedGoogle Scholar
  24. 24.
    Liippo J, Pummi K, Hohenthal U, Lammintausta K. Patch testing and sensitization to multiple drugs. Contact Dermatitis. 2013;69:296–302. doi: 10.1111/cod.12076.PubMedGoogle Scholar
  25. 25.
    Gex-Collet C, Helbling A, Pichler WJ. Multiple drug hypersensitivity–proof of multiple drug hypersensitivity by patch and lymphocyte transformation tests. J Investig Allergol Clin Immunol. 2005;15:293–6.PubMedGoogle Scholar
  26. 26.
    Ozkaya E. Independent lesions of fixed drug eruption due to cotrimoxazole and tenoxicam in the same patient: A rare case of polysensitivity. J Am Acad Dermatol. 2004;51(2Suppl):S102–4.Google Scholar
  27. 27.
    Özkaya E. Polysensitivity in fixed drug eruption due to a novel drug combination: independent lesions due to piroxicam and cotrimoxazole. Eur J Dermatol. 2006;16:591–2.PubMedGoogle Scholar
  28. 28.
    Barbaud A, Trechot P, Reichert-Penetrat S, Commun N, Schmutz JL. Relevance of skin tests with drugs in investigating cutaneous adverse drug reactions. Contact Dermatitis. 2001;45:265–8.PubMedGoogle Scholar
  29. 29.
    Barbaud A, Béné MC, Faure G, Schmutz JL. Skin tests in the study of drug eruptions with suspected immuno-allergic mechanism. Bull Acad Natl Med. 2000;184:775–91.PubMedGoogle Scholar
  30. 30.
    Özkaya E. Current understanding of Baboon Syndrome. Expert Rev Dermatol. 2009;4:163–75.Google Scholar
  31. 31.
    Kellett JK, King CM, Beck MH. Compound allergy to medicaments. Contact Dermatitis. 1986;14:45–8.PubMedGoogle Scholar
  32. 32.
    Zawar V, Kirloskar M, Chuh A. Fixed drug eruption – a sexually inducible reaction? Int J STD AIDS. 2004;15:560–3.PubMedGoogle Scholar
  33. 33.
    Gonçalo M, Bruynzeel DP. Patch testing in adverse drug reactions. In: Johansen JD, Frosch PJ, Lepoittevin J-P, editors. Contact dermatitis. 5th ed. Berlin: Springer; 2011. p. 475–91.Google Scholar
  34. 34.
    Sánchez TS, Sánchez-Pérez J, Aragüés M, García-Díaz A. Flare-up reaction of pseudoephedrine baboon syndrome after positive patch test. Contact Dermatitis. 2000;42:312–3.PubMedGoogle Scholar
  35. 35.
    van Ketel WG. Patch testing in penicillin allergy. Contact Dermatitis. 1975;1:253–4.PubMedGoogle Scholar
  36. 36.
    Sasseville D. The role of skin testing in drug eruptions. http://www.dermatologyrounds.ca/crus/dermaeng_050602.pdf. Accessed 26 Apr 2014.
  37. 37.
    Barbaud A. Drug skin tests and systemic drug reactions: an update. Expert Rev Dermatol. 2007;2:481–95.Google Scholar
  38. 38.
    Santiago F, Gonçalo M, Vieira R, Coelho S, Figueiredo A. Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermatitis. 2010;62:47–53. doi: 10.1111/j.1600-0536.2009.01659.x.PubMedGoogle Scholar
  39. 39.
    Mayo-Pampín E, Flórez A, Feal C, Conde A, Abalde MT, De la Torre C, et al. Acute generalized exanthematous pustulosis due to pseudoephedrine with positive patch test. Acta Derm Venereol. 2006;86:542–3.PubMedGoogle Scholar
  40. 40.
    Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168:555–62. doi: 10.1111/bjd.12125.PubMedGoogle Scholar
  41. 41.
    Moreno-Escobosa MC, de las Heras M, Figueredo E, Umpiérrez A, Bombin C, Cuesta J. Generalized dermatitis due to pseudoephedrine. Allergy. 2002;57:753.PubMedGoogle Scholar
  42. 42.
    Terui T, Tagami H. Eczematous drug eruption from carbamazepine: coexistence of contact and photocontact sensitivity. Contact Dermatitis. 1989;20:260–4.PubMedGoogle Scholar
  43. 43.
    Özkaya E, Güngör H. Carbamazepine induced eczematous eruption clinically resembling atopic dermatitis. J Eur Acad Dermatol Venereol. 1999;12:182–3.Google Scholar
  44. 44.
    Yawalkar N, Hari Y, Frutig K, Egli F, Wendland T, Braathen LR, et al. T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic. J Invest Dermatol. 2000;115:647–52.PubMedGoogle Scholar
  45. 45.
    Bruynzeel DP, Van Ketel WG. Skin tests in the diagnosis of maculopapular drug eruptions. Semin Dermatol. 1987;6:119–24.Google Scholar
  46. 46.
    Barbaud AM, Béné MC, Schmutz JL, Ehlinger A, Weber M, Faure GC. Role of delayed cellular hypersensitivity and adhesion molecules in maculopapular rashes induced by amoxicillin. Arch Dermatol. 1997;133:481–6.PubMedGoogle Scholar
  47. 47.
    Padial A, Antunez C, Blanca-Lopez N, Fernandez TD, Cornejo-Garcia JA, Mayorga C, et al. Non-immediate reactions to betalactams: diagnostic value of skin testing and drug provocation test. Clin Exp Allergy. 2008;38:822–8. doi: 10.1111/j.1365-2222.2008.02961.x.PubMedGoogle Scholar
  48. 48.
    Duve S, Worret W, Hofmann H. The baboon syndrome: a manifestation of haematogenous contact-type dermatitis. Acta Derm Venereol. 1994;74:480–1.PubMedGoogle Scholar
  49. 49.
    Wakelin SH, Sidhu S, Orton DI, Chia Y, Shaw S. Amoxycillin-induced flexural exanthem. Clin Exp Dermatol. 1999;24:71–3.PubMedGoogle Scholar
  50. 50.
    Köhler LD, Schönlein K, Kautzky F, Vogt HJ. Diagnosis at first glance: the baboon syndrome. Int J Dermatol. 1996;35:502–3.PubMedGoogle Scholar
  51. 51.
    Arnold AW, Häusermann P, Bach S, Bircher AJ. Recurrent flexural exanthema (SDRIFE or baboon syndrome) after administration of two different iodinated radio contrast media. Dermatology. 2007;214:89–93.PubMedGoogle Scholar
  52. 52.
    Ozkaya E, Bayazit H, Ozarmagan G. Topical provocation in 27 cases of cotrimoxazole-induced fixed drug eruption. Contact Dermatitis. 1999;41:185–9.Google Scholar
  53. 53.
    Wolkenstein P, Chosidow O, Fléchet ML, Robbiola O, Paul M, Dumé L, et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis. 1996;35:234–6.PubMedGoogle Scholar
  54. 54.
    Harries MJ, McIntyre SJ, Kingston TP. Co-amoxiclav-induced acute generalized exanthematous pustulosis confirmed by patch testing. Contact Dermatitis. 2006;55:372.PubMedGoogle Scholar
  55. 55.
    Padial MA, Alvarez-Ferreira J, Tapia B, et al. Acute generalized exanthematous pustulosis associated with pseudoephedrine. Br J Dermatol. 2004;150:139–42.PubMedGoogle Scholar
  56. 56.
    Assier-Bonnet H, Viguier M, Dubertret L, Revuz J, Roujeau JC. Severe adverse drug reactions due to pseudoephedrine from over-the-counter medications. Contact Dermatitis. 2002;47:165–82.PubMedGoogle Scholar
  57. 57.
    Kempinaire A, De Raeve L, Merckx M, De Coninck A, Bauwens M, Roseeuw D. Terbinafine-induced acute generalized exanthematous pustulosis confirmed by a positive patch-test result. J Am Acad Dermatol. 1997;37:653–5.PubMedGoogle Scholar
  58. 58.
    Girardi M, Duncan KO, Tigelaar RE, Imaeda S, Watsky KL, McNiff JM. Cross-comparison of patch test and lymphocyte proliferation responses in patients with a history of acute generalized exanthematous pustulosis. Am J Dermatopathol. 2005;27:343–6.PubMedGoogle Scholar
  59. 59.
    Elzagallaai AA, Knowles SR, Rieder MJ, Bend JR, Shear NH, Koren G. Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Drug Saf. 2009;32:391–408.PubMedGoogle Scholar
  60. 60.
    Chauhan A, Anand S, Thomas S, Subramanya HC, Pradhan G. Carbamazepine induced DRESS syndrome. J Assoc Physicians India. 2010;58:634–6.PubMedGoogle Scholar
  61. 61.
    Liao HT, Hung KL, Wang CF, Chen WC. Patch testing in the detection of cutaneous reactions caused by carbamazepine. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1997;38:365–9.PubMedGoogle Scholar
  62. 62.
    Alanko K. Patch testing in cutaneous reactions caused by carbamazepine. Contact Dermatitis. 1993;29:254–7.PubMedGoogle Scholar
  63. 63.
    Lin YT, Chang YC, Hui RC, Yang CH, Ho HC, Hung SI, Chung WH. A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions. J Eur Acad Dermatol Venereol. 2013;27:356–64. doi: 10.1111/j.1468-3083.2011.04418.x.PubMedGoogle Scholar
  64. 64.
    Emmett EA. Drug photoallergy. Int J Dermatol. 1978;17:370–9.PubMedGoogle Scholar
  65. 65.
    Schwarze HP, Albes B, Marguery MC, Loche F, Bazex J. Evaluation of drug-induced photosensitivity by UVB photopatch testing. Contact Dermatitis. 1998;39:200.PubMedGoogle Scholar
  66. 66.
    Drucker AM, Rosen CF. Drug-induced photosensitivity: culprit drugs, management and prevention. Drug Saf. 2011;34:821–37. doi: 10.2165/11592780-000000000-00000.PubMedGoogle Scholar
  67. 67.
    Lee AY, Joo HJ, Chey WY, Kim YG. Photopatch testing in seven cases of photosensitive drug eruptions. Ann Pharmacother. 2001;35:1584–7.PubMedGoogle Scholar
  68. 68.
    White IR. Photopatch test in a hydrochlorothiazide drug eruption. Contact Dermatitis. 1983;9:237.PubMedGoogle Scholar
  69. 69.
    Lee AY, Jung SY. Two patients with isoniazid-induced photosensitive lichenoid eruptions confirmed by photopatch test. Photodermatol Photoimmunol Photomed. 1998;14:77–8.PubMedGoogle Scholar
  70. 70.
    Marguery MC, Chouini-Lalanne N, Drugeon C, Gadroy A, Bayle P, Journe F, et al. UV-B phototoxic effects induced by atorvastatin. Arch Dermatol. 2006;142:1082–4.Google Scholar
  71. 71.
    Nino M, Patruno C, Zagaria O, Balato N. Allergic contact dermatitis from heparin-containing gel: use of scratch patch test for diagnosis. Dermatitis. 2009;20:171–2.PubMedGoogle Scholar
  72. 72.
    Conilleau V, Dompmartin A, Michel M, Verneuil L, Leroy D. Photoscratch testing in systemic drug-induced photosensitivity. Photodermatol Photoimmunol Photomed. 2000;16:62–6.PubMedGoogle Scholar
  73. 73.
    Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol. 2005;152:968–74.PubMedGoogle Scholar
  74. 74.
    Gaig P, San Miguel-Moncin MM, Bartra J, Bonet A, García-Ortega P. Usefulness of patch tests for diagnosing selective allergy to captopril. J Investig Allergol Clin Immunol. 2001;11:204–6.PubMedGoogle Scholar
  75. 75.
    Watanabe K, Nishimura K, Shiode M, Sekiya M, Ikeda S, Inoue Y, et al. Captopril, an angiotensin-converting enzyme inhibitor, induced pulmonary infiltration with eosinophilia. Intern Med. 1996;35:142–5.PubMedGoogle Scholar
  76. 76.
    Knowles S, Gupta AK, Shear NH. The spectrum of cutaneous reactions associated with diltiazem: three cases and a review of the literature. J Am Acad Dermatol. 1998;38:201–6.PubMedGoogle Scholar
  77. 77.
    Cnudde F, Leynadier F, Dry J. Cutaneous reaction to captopril: value of patch tests. Contact Dermatitis. 1990;23:375–6.PubMedGoogle Scholar
  78. 78.
    Pfützner W, Rueff F, Przybilla B. Systemic contact dermatitis due to captopril without cross-sensitivity to fosinopril, quinapril and benazepril. Acta Derm Venereol. 2004;84:91–2.PubMedGoogle Scholar
  79. 79.
    Martinez JC, Fuentes MJ, Armentia A, Vega JM, Fernandez A. Dermatitis to captopril. Allergol Immunopathol (Madr). 2001;29:279–80.Google Scholar
  80. 80.
    Chaabane A, Fadhl NB, Chadly Z, Fredj NB, Boughattas NA, Aouam K. Captopril-induced DRESS: first reported case confirmed by patch test. Dermatitis. 2013;24:255–7.PubMedGoogle Scholar
  81. 81.
    Smit AJ, Van der Laan S, De Monchy J, Kallenberg CG, Donker AJ. Cutaneous reactions to captopril. Predictive value of skin tests. Clin Allergy. 1984;14:413–9.PubMedGoogle Scholar
  82. 82.
    Balieva F, Steinkjer B. Contact dermatitis to captopril. Contact Dermatitis. 2009;61:177–8.PubMedGoogle Scholar
  83. 83.
    Pérez-Ferriols A, Martínez-Menchón T, Fortea JM. Follicular mucinosis secondary to captopril-induced photoallergy. Actas Dermosifiliogr. 2005;96:167–70.PubMedGoogle Scholar
  84. 84.
    Wagner SN, Welke F, Goos M. Occupational UVA-induced allergic photodermatitis in a welder due to hydrochlorothiazide and ramipril. Contact Dermatitis. 2000;43:245–6.PubMedGoogle Scholar
  85. 85.
    Rodríguez Granados MT, Abalde T, García Doval I, De la Torre C. Systemic photosensitivity to quinapril. J Eur Acad Dermatol Venereol. 2004;18:389–90.PubMedGoogle Scholar
  86. 86.
    Lluch-Bernal M, Novalbos A, Umpierrez A, Figueredo E, Bombin C, Sastre J. Cutaneous reaction to captopril with positive patch test and lack of cross-sensitivity to enalapril and benazepril. Contact Dermatitis. 1998;39:316–7.PubMedGoogle Scholar
  87. 87.
    Pfab F, Athanasiadis GI, Kollmar A, Ring J, Ollert M. Lichenoid drug eruption due to an antihypertonic drug containing irbesartan and hydrochlorothiazide. Allergy. 2006;61:786–7.PubMedGoogle Scholar
  88. 88.
    Vaillant L, Le Marchand D, Grognard C, Hocine R, Lorette G. Photosensitivity to methyldopa. Arch Dermatol. 1988;124:326–7.PubMedGoogle Scholar
  89. 89.
    Lang Jr PG. Quinidine-induced photodermatitis confirmed by photopatch testing. J Am Acad Dermatol. 1983;9:124–8.PubMedGoogle Scholar
  90. 90.
    Schürer NY, Lehmann P, Plewig G. Quinidine-induced photoallergy. A clinical and experimental study. Hautarzt. 1991;42:158–61.PubMedGoogle Scholar
  91. 91.
    Higa K, Hirata K, Dan K. Mexiletine-induced severe skin eruption, fever, eosinophilia, atypical lymphocytosis, and liver dysfunction. Pain. 1997;73:97–9.PubMedGoogle Scholar
  92. 92.
    Yagami A, Yoshikawa T, Asano Y, Koie S, Shiohara T, Matsunaga K. Drug-induced hypersensitivity syndrome due to mexiletine hydrochloride associated with reactivation of human herpesvirus 7. Dermatology. 2006;213:341–4.PubMedGoogle Scholar
  93. 93.
    Lee SP, Kim SH, Kim TH, Sohn JW, Shin DH, Park SS, et al. A case of mexiletine-induced hypersensitivity syndrome presenting as eosinophilic pneumonia. J Korean Med Sci. 2010;25:148–51.PubMedCentralPubMedGoogle Scholar
  94. 94.
    Morito H, Ogawa K, Kobayashi N, Fukumoto T, Asada H. Drug-induced hypersensitivity syndrome followed by persistent arthritis. J Dermatol. 2012;39:178–9. doi: 10.1111/j.1346-8138.2011.01236.x.PubMedGoogle Scholar
  95. 95.
    Sasaki K, Yamamoto T, Kishi M, Yokozeki H, Nishioka K. Acute exanthematous pustular drug eruption induced by mexiletine. Eur J Dermatol. 2001;11:469–71.PubMedGoogle Scholar
  96. 96.
    Jappe U, Uter W, Menezes de Pádua CA, Herbst RA, Schnuch A. Allergic contact dermatitis due to beta-blockers in eye drops: a retrospective analysis of multicentre surveillance data 1993–2004. Acta Derm Venereol. 2006;86:509–14.PubMedGoogle Scholar
  97. 97.
    Neumark M, Moshe S, Ingber A, Slodownik D. Occupational airborne contact dermatitis to simvastatin, carvedilol, and zolpidem. Contact Dermatitis. 2009;61:51–2. doi: 10.1111/j.1600-0536.2009.01555.x.PubMedGoogle Scholar
  98. 98.
    Zaccaria E, Gualco F, Drago F, Rebora A. Fixed drug eruption due to propranolol. Acta Derm Venereol. 2006;86:371.PubMedGoogle Scholar
  99. 99.
    Giner Esparza MA, Miedes Pitarch E, Miquel Miquel FJ, Palop Larrea V. Fixed drug eruption and bisoprolol. Aten Primaria. 2009;41:351.PubMedGoogle Scholar
  100. 100.
    Palungwachira P, Palungwachira P. Fixed drug eruption due to atenolol: a case report. J Med Assoc Thai. 1999;82:1158–61.PubMedGoogle Scholar
  101. 101.
    Belhadjali H, Trimech O, Youssef M, Elhani I, Zili J. Fixed drug eruption induced by atenolol. Clin Cosmet Investig Dermatol. 2009;1:37–9.PubMedCentralPubMedGoogle Scholar
  102. 102.
    Miyauchi H, Horiki S, Horio T. Clinical and experimental photosensitivity reaction to tilisolol hydrochloride. Photodermatol Photoimmunol Photomed. 1994;10:255–8.PubMedGoogle Scholar
  103. 103.
    Zachary CB, Slater DN, Holt DW, Storey GC, MacDonald DM. The pathogenesis of amiodarone-induced pigmentation and photosensitivity. Br J Dermatol. 1984;110:451–6.PubMedGoogle Scholar
  104. 104.
    Ferguson J, Addo HA, Jones S, Johnson BE, Frain-Bell W. A study of cutaneous photosensitivity induced by amiodarone. Br J Dermatol. 1985;113:537–49.PubMedGoogle Scholar
  105. 105.
    Cholez C, Trechot P, Schmutz JL, Faure G, Bene MC, Barbaud A. Maculopapular rash induced by diltiazem: allergological investigations in four patients and cross reactions between calcium channel blockers. Allergy. 2003;58:1207–9.PubMedGoogle Scholar
  106. 106.
    Wakelin SH, James MP. Diltiazem-induced acute generalised exanthematous pustulosis. Clin Exp Dermatol. 1995;20:341–4.PubMedGoogle Scholar
  107. 107.
    Vicente-Calleja JM, Aguirre A, Landa N, Crespo V, Gonzalez-Perez R, Diaz-Perez JL. Acute generalized exanthematous pustulosis due to diltiazem: confirmation by patch testing. Br J Dermatol. 1997;137:837–9.PubMedGoogle Scholar
  108. 108.
    Jan V, Machet L, Gironet N, Martin L, Machet MC, Lorette G, et al. Acute generalized exanthematous pustulosis induced by diltiazem: value of patch testing. Dermatology. 1998;197:274–5.PubMedGoogle Scholar
  109. 109.
    Gesierich A, Rose C, Brocker EB, Trautmann A, Leverkus M. Acute generalised exanthematous pustulosis with subepidermal blisters of the distal extremities induced by diltiazem. Dermatology. 2006;213:48–9.PubMedGoogle Scholar
  110. 110.
    Gensch K, Hodzic-Avdagic N, Megahed M, Ruzicka T, Kuhn A. Acute generalized exanthematous pustulosis with confirmed type IV allergy. Report of 3 cases. Hautarzt. 2007;58(250–2):254–5.Google Scholar
  111. 111.
    Serrão V, Caldas Lopes L, Campos Lopes JM, Lobo L, Ferreira A. Acute generalized exanthematous pustulosis associated with diltiazem. Acta Med Port. 2008;21:99–102.PubMedGoogle Scholar
  112. 112.
    Gonzalo Garijo MA, Perez Calderon R, de Argila Fernandez-Duran D, Rangel Mayoral JF. Cutaneous reactions due to diltiazem and cross reactivity with other calcium channel blockers. Allergol Immunopathol (Madr). 2005;33:238–40.Google Scholar
  113. 113.
    Nucera E, Schavino D, Roncallo C, de Pasquale T, Buonomo A, Pollastrini E, et al. Delayed-type allergy to oral nimodipine. Contact Dermatitis. 2002;47:246–7.PubMedGoogle Scholar
  114. 114.
    Addo HA, Ferguson J, Frain-Bell W. Thiazide-induced photosensitivity: a study of 33 subjects. Br J Dermatol. 1987;116:749–60.PubMedGoogle Scholar
  115. 115.
    Masuoka E, Bito T, Shimizu H, Nishigori C. Dysfunction of melanocytes in photoleukomelanoderma following photosensitivity caused by hydrochlorothiazide. Photodermatol Photoimmunol Photomed. 2011;27:328–30.PubMedGoogle Scholar
  116. 116.
    Lehmann P, Hölzle E, Plewig G. Photoallergy to Neotri and cross reaction to tenoretic–detection by systemic photoprovocation. Hautarzt. 1988;39:38–41.PubMedGoogle Scholar
  117. 117.
    Prichard BN, Brogden RN. Xipamide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs. 1985;30:313–32.PubMedGoogle Scholar
  118. 118.
    Fernández de Corres L, Bernaola G, Fernández E, Leanizbarrutia I, Muñoz D. Photodermatitis from triamterene. Contact Dermatitis. 1987;17:114–5.PubMedGoogle Scholar
  119. 119.
    Schon MP, Tebbe B, Trautmann C, Orfanos CE. Lichenoid drug eruption induced by spironolactone. Acta Derm Venereol. 1994;74:476.PubMedGoogle Scholar
  120. 120.
    Aouam K, Ali HB, Youssef M, Chaabane A, Hamdi MH, Boughattas NA, et al. Lichenoid eruption associated with hydrochlorothiazide and possible cross reactivity to furosemide. Therapie. 2009;64:344–7.PubMedGoogle Scholar
  121. 121.
    Alonso JC, Ortega FJ, Gonzalo MJ, Palla PS. Cutaneous reaction to oral spironolactone with positive patch test. Contact Dermatitis. 2002;47:178–9.PubMedGoogle Scholar
  122. 122.
    Jachiet M, Bellon N, Assier H, Amsler E, Gaouar H, Pecquet C, et al. Cutaneous adverse drug reaction to oral acetazolamide and skin tests. Dermatology. 2013;226:347–52. doi: 10.1159/000350939.PubMedGoogle Scholar
  123. 123.
    Garg A, Smith W. Sulfur allergies can be misleading. J Pharm Pract Res. 2013;43:332.Google Scholar
  124. 124.
    Lee AG, Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? Ann Pharmacother. 2005;39:290–301.Google Scholar
  125. 125.
    Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. Contact Dermatitis. 2004;51:57–62.PubMedGoogle Scholar
  126. 126.
    Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. Pharmacotherapy. 2004;24:856–70.PubMedGoogle Scholar
  127. 127.
    De Barrio M, Tornero P, Zubeldia JM, Sierra Z, Matheu V, Herrero T. Fixed drug eruption induced by indapamide. Cross-reactivity with sulfonamides. J Investig Allergol Clin Immunol. 1998;8:253–5.PubMedGoogle Scholar
  128. 128.
    Jacob SE, Zapolanski T, Chayavichitsilp P. Sensitivity to para-phenylenediamine and intolerance to hydrochlorothiazide. Dermatitis. 2008;19:E44–5.PubMedGoogle Scholar
  129. 129.
    Romano A, Giovannetti A, Caruso C, Rosato E, Pierdominici M, Salsano F. Delayed hypersensitivity to bosentan. Allergy. 2009;64:499–501. doi: 10.1111/j.1398-9995.2008.01927.x.PubMedGoogle Scholar
  130. 130.
    Allanore Y, Moachon L, Maury E, Isvy A, Kahan A. Bosentan-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. J Rheumatol. 2010;37:1077–8. doi: 10.3899/jrheum.091266.PubMedGoogle Scholar
  131. 131.
    de Boer EM, Bruynzeel DP. Allergy to pravastatin. Contact Dermatitis. 1994;30:238.PubMedGoogle Scholar
  132. 132.
    Peramiquel L, Serra E, Dalmau J, Vila AT, Mascaró JM, Alomar A. Occupational contact dermatitis from simvastatin. Contact Dermatitis. 2005;52:286–7.PubMedGoogle Scholar
  133. 133.
    Field S, Bourke B, Hazelwood E, Bourke JF. Simvastatin - occupational contact dermatitis. Contact Dermatitis. 2007;57:282–3.PubMedGoogle Scholar
  134. 134.
    Granados MT, de la Torre C, Cruces MJ, Piñeiro G. Chronic actinic dermatitis due to simvastatin. Contact Dermatitis. 1998;38:294–5.PubMedGoogle Scholar
  135. 135.
    Machet L, Vaillant L, Jan V, Lorette G. Fenofibrate-induced photosensitivity: value of photopatch testing. J Am Acad Dermatol. 1997;37:808–9.PubMedGoogle Scholar
  136. 136.
    Leenutaphong V, Manuskiatti W. Fenofibrate-induced photosensitivity. J Am Acad Dermatol. 1996;35:775–7.PubMedGoogle Scholar
  137. 137.
    Hong JB, Wang SH, Chu CY. Fenofibrate-induced photosensitivity-a case report and literature review. Dermatol Sin. 2009;27:37–43.Google Scholar
  138. 138.
    Gardeazabal J, Gonzalez M, Izu R, Gil N, Aguirre A, Diaz-Perez JL. Phenofibrate-induced lichenoid photodermatitis. Photodermatol Photoimmunol Photomed. 1993;9:156–8.PubMedGoogle Scholar
  139. 139.
    Leenutaphong V. Reply: Fenofibrate-induced photosensitivity: value of photopatch testing. J Am Acad Dermatol. 1997;37:809.Google Scholar
  140. 140.
    Serrano G, Fortea JM, Latasa JM, Millan F, Janes C, Bosca F, et al. Photosensitivity induced by fibric acid derivatives and its relation to photocontact dermatitis to ketoprofen. J Am Acad Dermatol. 1992;27(2 Pt 1):204–8.PubMedGoogle Scholar
  141. 141.
    Carrozza P, Gabutti L, Gilliet F, Marone C. Heparin-induced systemic inflammatory response syndrome with progressive skin necrosis in haemodialysis. Nephrol Dial Transplant. 1997;2:2424–7.Google Scholar
  142. 142.
    Enrique E, Alijotas J, Cistero A, san Miguel MM, Bartra J, Tresserra F. Patch-test positivity in cutaneous reactions to enoxaparin. Contact Dermatitis. 2000;42:43.PubMedGoogle Scholar
  143. 143.
    Oldhoff JM, Bihari IC, Knol EF, Bruijnzeel-Koomen CA, de Bruin-Weller MS. Atopy patch test in patients with atopic eczema/dermatitis syndrome: comparison of petrolatum and aqueous solution as a vehicle. Allergy. 2004;59:451–6.PubMedGoogle Scholar
  144. 144.
    Méndez J, Sanchís ME, de la Fuente R, Stolle R, Vega JM, Martínez C, et al. Delayed-type hypersensitivity to subcutaneous enoxaparin. Allergy. 1998;53:999–1003.PubMedGoogle Scholar
  145. 145.
    Koch P, Münssinger T, Rupp-John C, Uhl K. Delayed-type hypersensitivity skin reactions caused by subcutaneous unfractionated and low-molecular-weight heparins: tolerance of a new recombinant hirudin. J Am Acad Dermatol. 2000;42:612–9.PubMedGoogle Scholar
  146. 146.
    Grims RH, Weger W, Reiter H, Arbab E, Kränke B, Aberer W. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight. Br J Dermatol. 2007;157:514–7.PubMedGoogle Scholar
  147. 147.
    Zollner TM, Gall H, Volpel H, Kaufmann R. Type IV allergy to natural hirudin confirmed by in vitro stimulation with recombinant hirudin. Contact Dermatitis. 1996;35:59–60.PubMedGoogle Scholar
  148. 148.
    Hohenstein E, Tsakiris D, Bircher AJ. Delayed-type hypersensitivity to the ultra-low-molecular-weight heparin fondaparinux. Contact Dermatitis. 2004;51:149–51.PubMedGoogle Scholar
  149. 149.
    Trautmann A, Seitz CS. Heparin allergy: delayed-type non-IgE-mediated allergic hypersensitivity to subcutaneous heparin injection. Immunol Allergy Clin North Am. 2009;29:469–80.PubMedGoogle Scholar
  150. 150.
    Jappe U, Reinhold D, Bonnekoh B. Arthus reaction to lepirudin, a new recombinant hirudin, and delayed-type hypersensitivity to several heparins and heparinoids, with tolerance to its intravenous administration. Contact Dermatitis. 2002;46:29–32.PubMedGoogle Scholar
  151. 151.
    Frouin E, Roth B, Grange A, Grange F, Tortel MC, Guillaume JC. Hypersensitivity to fluindione (Previscan). Positive skin patch tests. Ann Dermatol Venereol. 2005;132(12 Pt 1):1000–2.PubMedGoogle Scholar
  152. 152.
    Chtioui M, Cousin-Testard F, Zimmermann U, Amar A, Saiag P, Mahé E. Fluindione-induced acute generalised exanthematous pustulosis confirmed by patch testing. Ann Dermatol Venereol. 2008;135:295–8.PubMedGoogle Scholar
  153. 153.
    López Abad R, Iriarte Sotés P, Castro Murga M, Gracia Bara MT, Sesma Sánchez P. Fixed drug eruption induced by phenylephrine: a case of polysensitivity. J Investig Allergol Clin Immunol. 2009;19:322–3.PubMedGoogle Scholar
  154. 154.
    Barranco R, Rodríguez A, de Barrio M, Trujillo MJ, de Frutos C, Matheu V, et al. Sympathomimetic drug allergy: cross-reactivity study by patch test. Am J Clin Dermatol. 2004;5:351–5.PubMedGoogle Scholar
  155. 155.
    Cheema AN, Mohammad A, Hong T, Jakubovic HR, Parmar GS, Sharieff W, et al. Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation. J Am Coll Cardiol. 2011;58:1445–54.PubMedGoogle Scholar
  156. 156.
    Garcia CM, Carmena R, Garcia R, Berges P, Camacho E, Cotter MP, et al. Fixed drug eruption from ticlopidine, with positive lesional patch test. Contact Dermatitis. 2001;44:40–1.PubMedGoogle Scholar
  157. 157.
    Cannavo SP, Borgia F, Guarneri F, Vaccaro M. Acute generalized exanthematous pustulosis following use of ticlopidine. Br J Dermatol. 2000;142:577–8.PubMedGoogle Scholar
  158. 158.
    Salava A, Alanko K, Hyry H. Dipyridamole-induced eczematous drug eruption with positive patch test reaction. Contact Dermatitis. 2012;67:103–4. doi: 10.1111/j.1600-0536.2012.02066.x.PubMedGoogle Scholar
  159. 159.
    Kawakami T, Fujita A, Takeuchi S, Muto S, Soma Y. Drug-induced hypersensitivity syndrome: drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by aspirin treatment of Kawasaki disease. J Am Acad Dermatol. 2009;60:146–9. doi: 10.1016/j.jaad.2008.07.044.PubMedGoogle Scholar
  160. 160.
    Miyamoto H, Okajima M. Allergic contact dermatitis from epsilon-aminocaproic acid. Contact Dermatitis. 2000;42:50.PubMedGoogle Scholar
  161. 161.
    González Gutiérrez ML, Esteban López MI, Ruíz Ruíz MD. Positivity of patch tests in cutaneous reaction to aminocaproic acid: 2 case reports. Allergy. 1995;50:745–6.PubMedGoogle Scholar
  162. 162.
    Villarreal O. Systemic dermatitis with eosinophilia due to epsilon-aminocaproic acid. Contact Dermatitis. 1999;40:114.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Esen Özkaya
    • 1
  • Kurtuluş Didem Yazganoğlu
    • 1
  1. 1.Department of Dermatology and VenereologyIstanbul University Istanbul Medical FacultyIstanbulTurkey

Personalised recommendations